ecancermedicalscience

Conference Report

Cancer Immunotherapy: from the lab to clinical applications. Potential impact on cancer centres’ organisation

9 Nov 2016
Linda Cairns, Sandrine Aspeslagh, Andrea Anichini, Jon Amund Kyte, Christian Blank, Paolo Ascierto, Nicolle Rekers, Per Thor Straten, Ahmad Awada

This report covers the Immunotherapy sessions of the 2016 Organisation of European Cancer Institutes (OECI) Oncology Days meeting, which was held on 15th–17th June 2016 in Brussels, Belgium. Immunotherapy is a potential cancer treatment that uses an individual’s immune system to fight the tumour. In recent years significant advances have been made in this field in the treatment of several advanced cancers. Cancer immunotherapies include monoclonal antibodies that are designed to attack a very specific part of the cancer cell and immune checkpoint inhibitors which are molecules that stimulate or block the inhibition of the immune system. Other cancer immunotherapies include vaccines and T cell infusions. This report will summarise some of the research that is going on in this field and will give us an update on where we are at present.

Related Articles

Natalia Camejo, Camila Montenegro, Dahiana Amarillo, Cecilia Castillo, Gabriel Krygier
Gonzalo Javier Ziegler-Rodriguez, Miguel Ángel Pinillos Portella, Gabriel De la Cruz Ku, Sheila Eunice Vílchez Santillan, Jorge Dunstan Yataco, José Antonio Galarreta Zegarra, Gabriela Calderón Valencia, José Manuel Cotrina Concha
Lisa Ximena Rodríguez Rojas, Diana Vasquez-Forero, Juan José Albán, Liliana Doza, Sandra Murillo, Jorge Andrés Olave-Rodriguez, José Nastasi
Misbah Younus Soomro, Saqib Raza Khan, Hashim Ishfaq, Insia Ali, Mirza Rameez Samar, Arif Hameed, Nawazish Zehra, Munira Moosajee, Yasmin Abdul Rashid
Florence Dedey, Josephine Nsaful, Kirstyn E Brownson, Ruth Y Laryea, Nathaniel Coleman, John Tetteh, Joe-Nat Clegg-Lamptey, Benedict N L Calys-Tagoe